Could a Once-Daily pill replace Twice-Daily dosing for young transplant patients?
NCT ID NCT01294020
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tested whether children who had received an organ transplant (kidney, liver, heart, lung, or intestine) could safely switch from taking tacrolimus twice a day (Prograf) to a once-daily version (Advagraf). The goal was to see if the once-daily pill provided similar drug levels in the blood and was just as safe over one year. A total of 81 stable pediatric patients were enrolled, and the study also included long-term follow-up for those who continued on the once-daily medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Site BE21
Brussels, 1020, Belgium
-
Site BE22
Brussels, 1200, Belgium
-
Site CZ42
Prague, 150 06, Czechia
-
Site DE41
Heidelberg, 69120, Germany
-
Site FR31
Paris, 75743, France
-
Site FR32
Paris, 75743, France
-
Site FR33
Paris, 75908, France
-
Site FR34
Bron, 69677, France
-
Site FR35
Bron, 69677, France
-
Site GB61
Manchester, M27 4HA, United Kingdom
-
Site GB62
Birmingham, B4 6NH, United Kingdom
-
Site GB64
London, WC1 3JH, United Kingdom
-
Site IT74
Bergamo, 24127, Italy
-
Site IT75
Palermo, 90127, Italy
-
Site PL51
Warsaw, 04-730, Poland
-
Site PL52
Warsaw, 04-730, Poland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tacrolimus (Prograf and Advagraf)
What this could lead to
If successful, this could show that a once-daily version of tacrolimus works as well as the twice-daily version in children, potentially simplifying their medication schedule.
What could go wrong
This is a small, early-phase study (Phase 2) with only 81 children. It focuses on drug levels, not long-term outcomes, and results may not apply to all transplant types or ages.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.